NR AHTF
AU Manaka,H.; Kato,T.; Kurita,K.; Katagiri,T.; Shikama,Y.; Kujirai,K.; Kawanami,T.; Suzuki,Y.; Nihei,K.; Sasaki,H.; Yamada,S.; Hirota,K.; Kusaka,H.; Imai,T.
TI Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease
QU Neuroscience Letters 1992 May 11; 139(1): 47-9
PT journal article
AB We have established the radioimmunoassay for ubiquitin in the cerebrospinal fluid (CSF) and measured the ubiquitin concentration in CSF from 4 cases of neuropathologically verified Creutzfeldt-Jakob disease (CJD), 10 cases of multi-infarct dementia (MID), 7 cases of senile dementia of Alzheimer type (SDAT), and 18 controls. The normal values were determined to range from 7.3 to 21.0 ng/ml, 14.3 +/- 1.1 ng/ml in the mean +/- S.E.M. The CSF ubiquitin levels in the cases of MID and SDAT were 16.6 +/- 6.4 ng/ml and 21.3 +/- 6.1 ng/ml, respectively. In the cases of CJD, the CSF ubiquitin was markedly increased at the early and middle stages of the disease (230.6 ng/ml in Case 1, 107.6 ng/ml in Case 2, 212.5 ng/ml in Case 3, and 377.0 ng/ml in Case 4) and these gradually decreased as the disease progressed. The measurement of CSF ubiquitin seems useful to make an early diagnosis of CJD.
IN Mit einem Radioimmunassay wiesen die Autoren in Rückenmarksflüssigkeit von 18 normalen Kontrollpersonen 7,3-21,0 ng/ml (im Durchschnitt 14,3 +/- 1,1 ng/ml), bei 10 Multiinfarktdemenspatienten 16,6 +/- 6,4 ng/ml, sowie bei 7 Alzheimer-Patienten 21.3 +/- 6.1 ng/ml Ubiquitin nach. Bei 4 Creutzfeldt-Jakob-Patienten waren es während der frühen und mittleren Krankheitsphasen 230,6 ng/ml, 107,6 ng/ml, 212,5 ng/ml, bzw. 377,0 ng/ml. In den Spätphasen nahmen die Ubiquitinkonzentrationen bei den Creutzfeldt-Jakob-Patienten wieder ab.
MH Aged; Alzheimer Disease/cerebrospinal fluid; Chromatography, High Pressure Liquid; Creutzfeldt-Jakob Syndrome/*cerebrospinal fluid; Dementia, Multi-Infarct/cerebrospinal fluid; Human; Middle Age; Radioimmunoassay; Ubiquitins/*cerebrospinal fluid/immunology
AD Hideo Manaka, Takeo Kato, Keiji Kurita, Tadashi Katagiri, Yukihiro Shikama, Kayoko Kujirai, Toru Kawanami, Yoshihiro Suzuki, Kuninobu Nihei, Hideo Sasaki, Third Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan; Shigeru Yamada, Koichi Hirota, Department of Neurology, Akita Red Cross Hospital, Akita, Japan; Hirofumi Kusaka and Terukuni Imai, Department of Neurology, Kitano Hospital, Osaka, Japan
SP englisch
PO Niederlande